Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Key Takeaway 4: Second-Line Regorafenib After TKI in HCC

August 15th 2019

Key Takeaway 3: Role of Frontline I/O Still Pending

August 15th 2019

Key Takeaway 2: Initial Systemic Therapy in HCC

August 15th 2019

Key Takeaway 1: Multidisciplinary Management of HCC

August 15th 2019

Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC

August 6th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

cfDNA Assay Emerges as Viable Option for MSI Detection

August 6th 2019

Cell-free DNA-based detection of microsatellite instability status was found to be highly concordant with tissue-based MSI testing.

Expert Advocates Universal Genetic Testing in Breast Cancer

August 5th 2019

Although research findings have established many applications for genetic information in breast cancer, not enough patients are being tested for the risk of germline mutations and new strategies are needed to broaden the clinical application of genomic advancements.

CMS Should Broaden Coverage for Germline Mutation Testing

July 31st 2019

Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.

The Future of Managing Gynecologic Cancer

July 30th 2019

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

PARP Inhibitor Mechanisms of Resistance

July 30th 2019

PARP Inhibitor Toxicity Management

July 30th 2019

Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

PARP Inhibitor Trial Updates

July 30th 2019

Treatment Options for Patients with BRCA1/2

July 30th 2019

Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019